Upgrades:
Canadian Natural Resources (NYSE:CNQ) (TSE:CNQ) was upgraded
by investment analysts at Goldman Sachs Group from a “neutral” rating to a
“buy” rating in a research note issued to investors on Thursday, The Fly
reports. The firm currently has a $21.00 price objective on the oil and gas
producer’s stock, up from their prior price objective of $15.00. Goldman Sachs
Group’s price target would suggest a potential upside of 30.52% from the
stock’s previous close.
A number of other brokerages have also commented on CNQ.
Wood & Company reaffirmed a “hold” rating on shares of Canadian Natural
Resources in a report on Friday, January 31st. UBS Group decreased their price
objective on Canadian Natural Resources from $55.00 to $28.00 and set a “buy”
rating on the stock in a report on Tuesday, March 31st. JPMorgan Chase &
Co. decreased their price objective on Canadian Natural Resources from $44.00
to $32.00 and set an “overweight” rating on the stock in a report on Wednesday,
March 11th. Royal Bank of Canada upped their price objective on Canadian
Natural Resources from $24.00 to $27.00 and gave the company an “outperform”
rating in a report on Friday, May 8th. Finally, Raymond James reissued a “buy”
rating on shares of Canadian Natural Resources in a report on Friday, March
6th. One analyst has rated the stock with a sell rating, five have assigned a
hold rating and ten have given a buy rating to the company’s stock. The company
currently has an average rating of “Buy” and a consensus target price of
$34.09. Read more …
Leggett & Platt (NYSE:LEG) was upgraded by analysts at
Raymond James from a “market perform” rating to a “strong-buy” rating in a
research note issued on Thursday, MarketBeat reports. The brokerage presently
has a $32.00 target price on the stock. Raymond James’ target price points to a
potential upside of 27.54% from the stock’s current price.
Several other equities research analysts also recently
commented on LEG. TheStreet downgraded Leggett & Platt from a “b” rating to
a “c+” rating in a report on Friday, March 6th. Zacks Investment Research
downgraded Leggett & Platt from a “hold” rating to a “sell” rating and set
a $28.00 price objective for the company. in a report on Wednesday, April 1st.
Stifel Nicolaus decreased their price objective on Leggett & Platt from
$49.00 to $20.00 and set a “hold” rating for the company in a report on Monday,
April 6th. Piper Sandler cut their target price on Leggett & Platt from
$47.00 to $35.00 and set a “neutral” rating on the stock in a research report
on Wednesday, April 15th. Finally, SunTrust Banks cut their target price on
Leggett & Platt from $29.00 to $27.00 and set a “hold” rating on the stock
in a research report on Wednesday, May 6th. One analyst has rated the stock
with a sell rating, six have issued a hold rating and one has given a strong
buy rating to the stock. Leggett & Platt has a consensus rating of “Hold”
and an average target price of $32.67. Read more …
Yum! Brands (NYSE:YUM) was upgraded by Stifel Nicolaus from
a “hold” rating to a “buy” rating in a research note issued to investors on
Thursday, The Fly reports.
Several other analysts have also recently issued reports on
the company. UBS Group cut their target price on Yum! Brands from $109.00 to
$105.00 and set a “buy” rating for the company in a research report on
Thursday, April 30th. Credit Suisse Group increased their target price on Yum!
Brands from $79.00 to $84.00 and gave the stock a “neutral” rating in a
research report on Thursday, April 30th. Morgan Stanley increased their target
price on Yum! Brands from $80.00 to $86.00 and gave the stock an “overweight”
rating in a research report on Thursday, April 30th. BTIG Research cut Yum!
Brands from a “buy” rating to a “neutral” rating in a research report on
Friday, February 7th. Finally, Wells Fargo & Co raised their price target
on Yum! Brands from $85.00 to $94.00 and gave the company an “equal weight”
rating in a report on Thursday, April 30th. One investment analyst has rated
the stock with a sell rating, eighteen have assigned a hold rating and six have
issued a buy rating to the company’s stock. The company has a consensus rating
of “Hold” and an average price target of $99.14. Read more …
Omega Healthcare Investors (NYSE:OHI) was upgraded by
investment analysts at Raymond James from an “outperform” rating to a
“strong-buy” rating in a research note issued on Friday, MarketBeat.com
reports. The firm currently has a $34.00 price objective on the real estate
investment trust’s stock, up from their previous price objective of $32.00.
Raymond James’ price target would indicate a potential upside of 29.23% from
the company’s current price.
Several other brokerages also recently commented on OHI.
Zacks Investment Research upgraded shares of Omega Healthcare Investors from a
“sell” rating to a “hold” rating in a research report on Thursday, April 23rd.
Capital One Financial raised shares of Omega Healthcare Investors from an
“equal weight” rating to an “overweight” rating and set a $33.00 price
objective on the stock in a research report on Tuesday, May 5th. Wells Fargo
& Co lowered their target price on shares of Omega Healthcare Investors
from $43.00 to $28.00 and set an “equal weight” rating on the stock in a report
on Thursday, March 26th. Citigroup decreased their price objective on shares of
Omega Healthcare Investors from $44.00 to $25.00 and set a “neutral” rating for
the company in a research note on Tuesday, April 7th. Finally, SunTrust Banks
decreased their price target on shares of Omega Healthcare Investors from
$36.00 to $32.00 and set a “hold” rating for the company in a research note on
Thursday, April 23rd. Two equities research analysts have rated the stock with
a sell rating, four have assigned a hold rating, four have issued a buy rating
and one has assigned a strong buy rating to the company’s stock. The company
has a consensus rating of “Hold” and an average target price of $35.10. Read more …
Cardinal Health (NYSE:CAH) was upgraded by research analysts
at UBS Group from a “neutral” rating to a “buy” rating in a report issued on
Friday, MarketBeat Ratings reports. The firm currently has a $64.00 target
price on the stock, up from their previous target price of $48.00. UBS Group’s
target price would indicate a potential upside of 35.31% from the company’s
previous close.
Several other equities analysts have also weighed in on the
stock. Barclays restated a “hold” rating and set a $54.00 price objective on
shares of Cardinal Health in a research report on Sunday, January 19th. Bank of
America raised shares of Cardinal Health from an “underperform” rating to a
“buy” rating and upped their price objective for the company from $57.00 to
$58.00 in a research note on Friday, March 20th. Morgan Stanley upped their
price objective on shares of Cardinal Health from $51.00 to $57.00 and gave the
company an “equal weight” rating in a research note on Tuesday. Cfra reduced
their price objective on shares of Cardinal Health from $61.00 to $58.00 and
set a “hold” rating for the company in a research note on Monday. Finally,
Mizuho upped their price objective on shares of Cardinal Health from $50.00 to
$56.00 and gave the company a “neutral” rating in a research note on Tuesday.
One equities research analyst has rated the stock with a sell rating, nine have
given a hold rating and three have given a buy rating to the stock. The stock
currently has an average rating of “Hold” and a consensus target price of
$57.64. Read more …
McKesson (NYSE:MCK) was upgraded by UBS Group from a
“neutral” rating to a “buy” rating in a research note issued to investors on
Friday, Marketbeat.com reports. The brokerage presently has a $160.00 price
target on the stock, up from their previous price target of $151.00. UBS
Group’s price target points to a potential upside of 17.26% from the stock’s
current price.
MCK has been the topic of several other reports. Morgan
Stanley reduced their price objective on McKesson from $182.00 to $150.00 and
set an “overweight” rating on the stock in a research note on Friday, March
27th. Goldman Sachs Group raised McKesson from a “neutral” rating to a “buy”
rating and boosted their price target for the stock from $173.00 to $174.00 in
a research report on Wednesday, March 18th. JPMorgan Chase & Co. boosted
their price target on McKesson from $186.00 to $187.00 and gave the stock an
“overweight” rating in a research report on Wednesday, March 18th. Deutsche
Bank boosted their price target on McKesson from $153.00 to $173.00 and gave
the stock a “hold” rating in a research report on Wednesday, February 5th.
Finally, Robert W. Baird raised McKesson from a “neutral” rating to an
“outperform” rating and boosted their price target for the stock from $164.00
to $197.00 in a research report on Friday, February 7th. One investment analyst
has rated the stock with a sell rating, five have given a hold rating and seven
have issued a buy rating to the company’s stock. McKesson presently has a
consensus rating of “Hold” and an average target price of $163.82. Read more …
Downgrades:
Novo Nordisk A/S (NYSE:NVO) was downgraded by stock analysts
at UBS Group from a “buy” rating to a “neutral” rating in a report issued on
Monday, The Fly reports.
Other analysts also recently issued reports about the stock.
Cowen began coverage on shares of Novo Nordisk A/S in a report on Monday, May
4th. They set a “market perform” rating and a $72.00 target price on the stock.
Societe Generale reissued a “sell” rating on shares of Novo Nordisk A/S in a
research note on Thursday. ValuEngine raised shares of Novo Nordisk A/S from a
“sell” rating to a “hold” rating in a research note on Tuesday, March 3rd.
Finally, Bank of America raised shares of Novo Nordisk A/S from a “neutral”
rating to a “buy” rating in a research report on Monday, March 16th. Two
analysts have rated the stock with a sell rating, seven have given a hold
rating and three have given a buy rating to the company. Novo Nordisk A/S has
an average rating of “Hold” and an average price target of $163.55. Read more …
Albemarle (NYSE:ALB) was downgraded by analysts at Goldman
Sachs Group from a “buy” rating to a “neutral” rating in a research report
issued to clients and investors on Tuesday, Briefing.com Automated Import
reports. They currently have a $61.00 target price on the specialty chemicals
company’s stock, down from their previous target price of $67.00. Goldman Sachs
Group’s price target would indicate a potential downside of 5.29% from the
stock’s previous close.
Several other research analysts have also recently issued
reports on the stock. Cfra decreased their price objective on shares of
Albemarle from $100.00 to $70.00 and set a “hold” rating for the company in a
report on Friday, April 3rd. Loop Capital cut shares of Albemarle from a “buy”
rating to a “sell” rating and decreased their price objective for the company
from $99.00 to $48.00 in a report on Wednesday, April 29th. ValuEngine cut
shares of Albemarle from a “hold” rating to a “sell” rating in a report on
Wednesday, April 15th. Vertical Research cut shares of Albemarle from a “buy”
rating to a “hold” rating in a report on Friday, February 21st. Finally, Zacks
Investment Research upgraded shares of Albemarle from a “sell” rating to a
“hold” rating and set a $67.00 price objective for the company in a report on
Monday. Six equities research analysts have rated the stock with a sell rating,
fifteen have issued a hold rating and seven have assigned a buy rating to the
stock. Albemarle presently has an average rating of “Hold” and a consensus
target price of $74.34. Read more …
Stanley Black & Decker (NYSE:SWK) was downgraded by
research analysts at Bank of America from a “buy” rating to a “neutral” rating
in a research report issued on Tuesday, Briefing.com Automated Import reports.
They currently have a $120.00 target price on the industrial products company’s
stock. Bank of America‘s price target indicates a potential upside of 5.65%
from the company’s previous close.
Several other brokerages have also commented on SWK. Nomura
Securities upped their price target on shares of Stanley Black & Decker
from $116.00 to $145.00 and gave the stock a “buy” rating in a research report
on Friday, April 17th. Morgan Stanley increased their price objective on shares
of Stanley Black & Decker from $125.00 to $130.00 and gave the stock an
“overweight” rating in a research report on Friday, May 1st. Nomura dropped
their price objective on shares of Stanley Black & Decker from $145.00 to
$131.00 in a research report on Monday, May 4th. JPMorgan Chase & Co. upped
their target price on shares of Stanley Black & Decker from $112.00 to
$130.00 and gave the company an “overweight” rating in a research note on
Monday, May 4th. Finally, Barclays restated a “buy” rating and issued a $132.00
target price on shares of Stanley Black & Decker in a research note on
Monday, April 6th. One analyst has rated the stock with a sell rating, six have
assigned a hold rating and twelve have issued a buy rating to the stock.
Stanley Black & Decker currently has a consensus rating of “Buy” and a
consensus price target of $148.76. Read more
Chevron (NYSE:CVX) was downgraded by equities research
analysts at UBS Group from a “buy” rating to a “neutral” rating in a research
note issued on Tuesday, Briefing.com Automated Import reports. They currently
have a $95.00 price target on the oil and gas company’s stock. UBS Group’s
target price would indicate a potential upside of 1.75% from the stock’s
previous close.
Other research analysts have also recently issued research
reports about the company. Wells Fargo & Co lifted their price objective on
Chevron from $107.00 to $111.00 and gave the company an “overweight” rating in
a research note on Monday, May 4th. Mizuho lowered their price objective on
Chevron from $140.00 to $100.00 and set a “buy” rating for the company in a
research note on Wednesday, April 8th. Independent Research cut Chevron to a
“hold” rating in a research note on Tuesday, April 14th. Raymond James
decreased their price target on Chevron from $125.00 to $105.00 and set an
“outperform” rating for the company in a research note on Tuesday, March 17th.
Finally, JPMorgan Chase & Co. boosted their price target on Chevron from
$97.00 to $103.00 and gave the stock an “overweight” rating in a research note
on Monday, May 4th. Seven analysts have rated the stock with a hold rating and
sixteen have given a buy rating to the stock. Chevron has an average rating of
“Buy” and an average target price of $113.05. Read more …
Medtronic (NYSE:MDT) was downgraded by investment analysts
at DZ Bank from a “buy” rating to a “hold” rating in a research report issued
to clients and investors on Thursday, Briefing.com Automated Import reports.
They presently have a $92.00 price target on the medical technology company’s stock.
DZ Bank’s target price would suggest a potential downside of 1.37% from the
company’s previous close.
Several other research firms have also recently commented on
MDT. Cfra upped their target price on shares of Medtronic from $126.00 to
$127.00 and gave the stock a “buy” rating in a research report on Tuesday,
February 18th. JPMorgan Chase & Co. decreased their target price on shares
of Medtronic from $128.00 to $115.00 and set an “overweight” rating for the
company in a research report on Thursday, April 9th. Raymond James decreased
their price objective on shares of Medtronic from $122.00 to $110.00 and set an
“outperform” rating for the company in a report on Thursday, April 9th. UBS
Group increased their price objective on shares of Medtronic from $127.00 to
$130.00 and gave the company a “buy” rating in a report on Thursday, January
16th. Finally, Piper Sandler reiterated a “buy” rating and issued a $135.00
price objective on shares of Medtronic in a report on Tuesday, February 18th.
Two research analysts have rated the stock with a sell rating, seven have
issued a hold rating and twenty-one have issued a buy rating to the company.
The stock currently has an average rating of “Buy” and an average target price
of $115.93. Read more …
No comments:
Post a Comment